ArticleBioMed research international2014
Can ki-67 play a role in prediction of breast cancer patients' response to neoadjuvant chemotherapy?
Article in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Machine learning-based prediction of disease-free survival in breast cancer patients with non-pathological complete response after neoadjuvant chemotherapy: a retrospective multicenter cohort study.American journal of cancer research · 2025Article
- Assessment of the Predictive Role of Ki-67 in Breast Cancer Patients' Responses to Neoadjuvant Chemotherapy.European journal of breast health · 2024Article
- Association of Proliferative Activity in Invasive Ductal Carcinoma Breast in Pakistani Population.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- A new pathological assessment method to assess residual lesions after neoadjuvant chemotherapy for breast cancer, residual disease in breast and nodes combined with Ki-67 (RDBN-K).Translational breast cancer research : a journal focusing on translational research in breast cancer · 2022Article
- Breast cancer resistance to chemotherapy: When should we suspect it and how can we prevent it?Annals of medicine and surgery (2012) · 2021Review
- Clinico-pathological characteristics among South African women with breast cancer receiving anti-retroviral therapy for HIV.Breast (Edinburgh, Scotland) · 2019Observational
- Immunohistochemical Evaluation of Ki-67 and Comparison with Clinicopathologic Factors in Breast CarcinomasAsian Pacific journal of cancer prevention : APJCP · 2019Article
- Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role ofOncotarget · 2018Article
- Ki67 Changes Identify Worse Outcomes in Residual Breast Cancer Tumors After Neoadjuvant Chemotherapy.The oncologist · 2018Article
- Article
- Prognostic Significance of Reduction in Ki67 Index After Neoadjuvant Chemotherapy in Patients With Breast Cancer in Kerman Between 2009 And 2014.Iranian journal of pathology · 2018Article
- Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.Breast cancer research and treatment · 2017Article
- Tumor Heterogeneity in Breast Cancer.Frontiers in medicine · 2017Review
- Meroxest improves the prognosis of immunocompetent C57BL/6 mice with allografts of E0771 mouse breast tumor cells.Archives of medical science : AMS · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrently the choice of breast cancer therapy is based on prognostic factors. The proliferation marker Ki-67 is used increasingly to determine the method of therapy. The current study analyses the predictive value of Ki-67 in foreseeing breast cancer patients' responses to neoadjuvant chemotherapy.
methodsThis study includes patients with invasive breast cancer treated between 2008 and 2013. The clinical response was assessed by correlating Ki-67 to histological examination, mammography, and ultrasonography findings.
resultsThe average Ki-67 value in our patients collectively (n = 77) is 34.9 ± 24.6%. The average Ki-67 value is the highest with 37.4 ± 24.0% in patients with a pCR. The Ki-67 values do not differ significantly among the 3 groups: pCR versus partial pathological response versus stable disease/progress (P = 0.896). However, Ki-67 values of patients with luminal, Her2 enriched, and basal-like cancers differed significantly from each other. Furthermore, within the group of luminal tumors Ki-67 values of patients with versus without pCR also differed significantly.
conclusionOur data shows that the Ki-67 value predicts the response to neoadjuvant chemotherapy as a function of the molecular subtype, reflecting the daily routine concerning Ki-67 and its impressing potential and limitation as a predictive marker for neoadjuvant chemotherapy response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.